Malignant cerebral infarction after ChAdOx1 nCov-19 vaccination: a catastrophic variant of vaccine-induced immune thrombotic thrombocytopenia

Article Medicine, General & Internal

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Merryn Voysey et al.

Summary: The ChAdOx1 nCoV-19 vaccine has been shown to have an acceptable safety profile and effectiveness against symptomatic COVID-19, with higher efficacy observed in the group that received a low dose followed by a standard dose.

LANCET (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Factor XIII and Fibrin Clot Properties in Acute Venous Thromboembolism

Michal Zabczyk et al.

Summary: FXIII is crucial in the modulation of fibrin clot properties in patients with VTE, impacting clot structure and function. FXIII activity is significantly reduced in acute PE and DVT patients, but gradually increases after the acute phase. Reduced FXIII activity is associated with impaired clot permeability and hypofibrinolysis in acute PE patients.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹

Article Medicine, General & Internal

US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021

Isaac See et al.

Summary: Cases of CVST with thrombocytopenia following Ad26.COV2.S vaccination have been reported in the US, leading to serious outcomes. This case series may provide guidance for clinical management and further investigation into the potential relationship between Ad26.COV2.S vaccine and CVST with thrombocytopenia.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Hematology

Successful treatment of vaccine-induced prothrombotic immune thrombocytopenia (VIPIT)

Johannes Thaler et al.

Summary: In cases of VIPIT following ChAdOx1 nCoV-19 vaccination, early initiation of treatment can effectively reduce the risk of thrombosis and lead to rapid improvement in the patient's health without thrombotic complications.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2021)

添加到收藏夹

Article Hematology

Thrombocytopenia with acute ischemic stroke and bleeding in a patient newly vaccinated with an adenoviral vector-based COVID-19 vaccine

Rolf Ankerlund Blauenfeldt et al.

Summary: This study reported the first Danish case of presumed inflammatory and thrombotic response following vaccination with the AZD1222 COVID-19 vaccine. The patient, a 60-year-old woman, experienced abdominal pain 7 days after vaccination, along with adrenal hemorrhages, ischemic stroke, and ultimately death. Blood tests revealed significant drops in platelet counts and increased D-dimer levels, suggesting a novel immune-mediated response to the vaccine.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2021)

添加到收藏夹

Article Medicine, General & Internal

Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination

Marie Scully et al.

Summary: 23 cases of thrombotic thrombocytopenia were reported after receiving the AstraZeneca vaccine, incited by antibodies to platelet factor 4 and unrelated to heparin therapy. Avoidance of platelet transfusion and consideration of nonheparin anticoagulant and intravenous immune globulin are recommended for treatment.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Letter Medicine, General & Internal

Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination

Kate-Lynn Muir et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination

Nina H. Schultz et al.

Summary: This study reports five cases of venous thrombosis and thrombocytopenia occurring 7 to 10 days after receiving the ChAdOx1 nCoV-19 vaccine, suggesting a rare vaccine-induced immune thrombotic thrombocytopenia. The condition, which can lead to catastrophic outcomes such as cerebral venous sinus thrombosis, may be treated with intravenous immune globulin.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Editorial Material Medicine, General & Internal

SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia

Douglas B. Cines et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

Andreas Greinacher et al.

Summary: After vaccination with ChAdOx1 nCov-19, rare immune thrombotic thrombocytopenia can occur due to platelet-activating antibodies against PF4, resulting in various thrombotic events. Most patients in this case series were women, with fatal outcomes such as cerebral venous thrombosis and intracranial hemorrhage. Additional studies are needed to further investigate and understand this phenomenon.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Letter Medicine, General & Internal

Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination - Response from the Manufacturer

Jerald Sadoff et al.

Summary: The manufacturer responds to recent reports of thrombosis and severe thrombocytopenia in recipients of the Ad26.COV2.S vaccine.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Hematology

Hypotheses behind the very rare cases of thrombosis with thrombocytopenia syndrome after SARS-CoV-2 vaccination

Jonathan Douxfils et al.

Summary: While the reported cases of thromboembolic events post-vaccination with AstraZeneca vaccine were lower than estimated rates in the general population, the European Medicines Agency concluded that there may be a very rare side effect of unusual thromboses with low blood platelets associated with the vaccine. Further investigations are needed to understand the potential relationship between vaccination and these rare events.

THROMBOSIS RESEARCH (2021)

添加到收藏夹

Article Medicine, General & Internal

Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study

Anton Pottegard et al.

Summary: This study assessed rates of cardiovascular and haemostatic events in Denmark and Norway after vaccination with the Oxford-AstraZeneca vaccine ChAdOx1-S, finding increased rates of venous thromboembolic events among recipients. Despite slightly higher rates of thrombocytopenia/coagulation disorders and bleeding, the overall safety outcomes were largely reassuring.

BMJ-BRITISH MEDICAL JOURNAL (2021)

添加到收藏夹

Letter Clinical Neurology